+ Watch ACUR
on My Watchlist
A pharmaceutical company engaged in research, development and manufacture of innovative Aversion(r) Technology and related product candidates.
Sadly, the best short ideas are often torpedoed by share unavailability or high borrowing costs. Such was the case with Acura, whose umpteenth price spike on a non-catalyst proved unshortable at either of my brokerages. I have to confess I can't understand the phenomenon - I've never been unable to buy shares of a stock, no matter how undervalued Seeking Alpha authors claim it to be, so why can't I short shares of a stock once it begins to "realize its true potential"? Rigged game, perhaps?I couldn't even bring myself to go over the details of Acura's PR today. Apparently they've managed to ward off generic competition for Oxecta, the drug from which they recognized one thousand dollars in revenue last quarter. Thank god they managed to protect that income stream. The only question about Acura that piques my interest is "will this charade go on forever"?
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions